RGNX

Regenxbio’s fundamental score is 5.5/10, reflecting moderate strength. Key positives include a high inventory turnover ratio (47.85) and strong gross profit margin (89.74%), which signal efficient operations and pricing power. However, risks are present in the net profit to total profit ratio (100%) and current assets turnover ratio (0.46), hinting at potential inefficiencies or liquidity concerns. The Asset-MV, Revenue-MV, and Cash-MV metrics place the company in mid-tier performance groups, with historical returns ranging from 1.47% to 20.82% over one month, underscoring the need for a balanced, evidence-based approach to valuation.